These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16227960)

  • 21. [Cancer of the prostate: current status of chemotherapy].
    Bollak C; Bergerat JP; Jacquemin D
    Bull Cancer; 1986; 73(1):61-4. PubMed ID: 3535934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal timing of chemotherapy in androgen independent prostate cancer.
    Schnadig ID; Beer TM
    Urol Oncol; 2009; 27(1):97-100. PubMed ID: 19111808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
    Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
    Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
    Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P
    Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Stadler WM; Michaelis LC; Ratain MJ
    J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
    [No Abstract]   [Full Text] [Related]  

  • 33. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
    Burgess EF; Roth BJ
    Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
    Flaig TW; Barqawi A; Miller G; Kane M; Zeng C; Crawford ED; Glodé LM
    Cancer; 2006 Jul; 107(2):266-74. PubMed ID: 16779800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The case for early chemotherapy for the treatment of metastatic disease.
    Lucas A; Petrylak DP
    J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.